Introduction
Traumatic brain injury (TBI) is a highly prevalent clinical issue affecting an estimated 1.7 million Americans annually [1] [2] [3] . TBI contributes to numerous pathophysiological conditions and adverse neuropsychiatric disturbances [4] . In many cases, extensive rehabilitative care is required. However, disinhibited behavior, including severe agitation and aggression, is common after moderate to severe TBI [5] [6] [7] [8] [9] [10] . Such symptoms pose a risk to the health and safety of patients and caregivers, as well as significantly impede rehabilitation [6] [7] [8] [9] [10] [11] . Management of agitation and aggression is therefore crucial, and typical and atypical antipsychotic drugs (APDs) are frequently employed to alleviate such issues. Extended use of these APDs, however, presents a number of possible problems, as evidence suggests they exacerbate motor and cognitive deficits and slow the rate of recovery [12] [13] [14] [15] .
Haloperidol (HAL) is a popular first-generation APD frequently used to manage post-TBI agitation. Preclinical studies using fluid percussion and cortical impact TBI models have demonstrated that chronic administration of HAL impairs motor and cognitive recovery [12] [13] [14] [15] . The impairment persists whether the drug is administered before or after behavioral testing, suggesting the deleterious effects are not due simply to behavioral sedation, and endure for up to three months after drug discontinuation [12, 15] . Like many of the APDs commonly used to alleviate post-TBI agitation, HAL exerts its effects by acting as a high-affinity D 2 receptor antagonist. Quetiapine (QUE), on the other hand, is a secondgeneration APD with considerably lower affinity for D 2 receptors [16, 17] . Prior research has demonstrated that neither single nor repeated administrations of the atypical APDs clozapine and olanzapine, both of which have D 2 receptor affinities comparable to that of QUE, has a negative impact on cognitive and motor performance after TBI [14, 18] . The rationale for evaluating QUE is that it is one of the most widely accepted treatments currently for managing agitation and aggression in the clinic.
When considering the use of antipsychotic medications to manage symptoms that may disrupt rehabilitation, treatment strategies may vary depending on short-term versus long-term needs and goals for patient care. Some evidence suggests that a single administration of HAL after injury does not disrupt cognitive and motor recovery except at high doses, while daily administration for five days exacerbates cognitive and neurobehavioral deficits [12, 13, 15, 19] . A realistic clinical strategy may rely on these medications prior to rehabilitation sessions and thus may not entail daily administration. However, the majority of research on APDs following TBI has focused on a daily drug regimen, the effects of which may differ from a periodic and potentially more clinically relevant administration schedule.
Hence, the present study aimed to evaluate the effects of continuous or intermittent treatment with QUE or HAL on short-term functional recovery after a controlled cortical impact (CCI) injury in adult male rats. The intermittent schedule was intended to simulate a clinically relevant course of drug administration where patients may not necessitate APD treatment every day. Motor function, spatial learning, and memory were assessed during this period to compare behavioral outcomes and how they may be affected by the APDs and the treatment schedule.
Materials and methods

Subjects and pre-surgical procedures
Seventy adult male rats (Harlan Sprague-Dawley, Indianapolis, IN) were paired housed in ventilated polycarbonate rat cages and maintained in a temperature (21 ± 1 • C) and light (on 0700-1900 h) controlled environment with food and water available ad libitum. During their week of acclimatization, the rats were pre-trained on the beam-walk task and then randomly assigned to one of the following group conditions: TBI + continuous vehicle (1.0 mL/kg; n = 10), TBI + continuous haloperidol (0.5 mg/kg; n = 10), TBI + continuous quetiapine (10 mg/kg; n = 10), TBI + intermittent haloperidol (0.5 mg/kg; n = 10), TBI + intermittent quetiapine (10 mg/kg; n = 10), and Sham controls for each condition (n = 20). All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Every attempt was made to limit the number of rats used and to minimize suffering.
Surgery
Controlled cortical impact (CCI) was produced as previously described [20] [21] [22] [23] . Briefly, surgical anesthesia was induced and maintained with 4% and 2% concentrations of isoflurane, respectively, in 2:1 N 2 O:O 2 . After endotracheal intubation the rats (275-300 g) were secured in a stereotaxic frame and ventilated mechanically. Core temperature was maintained at 37 ± 0.5 • C with a heating pad. Utilizing aseptic procedures a midline scalp incision was made, the skin and fascia were reflected to expose the skull, and a craniectomy (6-mm in diameter) was made in the right hemisphere with a hand held trephine. The bone flap was removed and the craniectomy was enlarged further to accommodate the impact tip (6 mm, flat), which was centered and lowered through the craniectomy until it touched the dura mater. Once confirmed that the impact tip was touching the dura, the rod was retracted and the impact tip was advanced 2.8 mm farther to produce a brain injury of moderate severity (2.8 mm tissue deformation at 4 m/s). Anesthesia was discontinued immediately after the impact and the incision was promptly sutured. The rats were subsequently extubated and assessed for acute neurological outcome. Sham rats underwent all surgical procedures, except the impact.
Acute neurological evaluation
Hind limb reflexive ability was assessed immediately following the cessation of anesthesia by gently squeezing the rats' paw every 5 s and recording the time to elicit a withdrawal response. Return of the righting reflex was determined by the time required to turn from the supine to prone position on three consecutive trials.
Drug administration
HAL (Sigma) and QUE (Tocris) were prepared daily by dissolving in 1:1 dimethyl sulfoxide (DMSO)/saline, which also served as the vehicle (VEH). The dose of HAL was chosen because it has been reported to be comparable to that used clinically to control psychosis [24] and has been used in several brain injury studies investigating functional outcome [12, 13, 15, 19, 25] . The dose of QUE was chosen based on the preclinical literature [26] . Treatments began 24 h after CCI or sham surgery and were provided intraperitoneally once daily or once every other day (i.e., intermittently) for 19 days. Both HAL and QUE were administered after the daily behavioral assessments to circumvent sedative effects, which would confound the results.
Motor performance: beam-balance and beam-walk
Motor function was assessed using the well-established beambalance and beam-walk tasks [20] [21] [22] [23] . Briefly, performance on the beam-balance is assessed by recording the time that the rats can maintain their balance on an elevated narrow wooden beam (90 cm above floor level, 1.5 cm wide, and 34 cm in length). The beamwalk task, modified from that originally devised by Feeney and colleagues [27] , and used extensively in our laboratory [20] [21] [22] [23] , consists of assessing rats using a negative-reinforcement paradigm to escape a bright light, shining at the start point, and white noise by traversing an elevated narrow beam (90 cm above floor level, 2.5 cm wide, and 100 cm in length) and entering a darkened goal box at the opposite end. Performance on the beam-walk consists of recording time to traverse the beam. The rats were trained prior to TBI or sham injury to perform the tasks without errors (i.e., maintain their balance for 60 s and traverse the beam in under 5 s). A baseline performance assessment was taken on the day of surgery. Performance was assessed on post-operative days 1-5 and consisted of three trials (60 s allotted time per trial) per day on each task. The average daily scores for each subject were used in the statistical analyses.
Cognitive performance: spatial learning
Spatial learning was assessed using a well-established Morris water maze (MWM) task [20] [21] [22] [23] 28] . Briefly, the maze consisted of a plastic pool (180 cm diameter; 60 cm high) filled with tap water (26 ± 1 • C) to a depth of 28 cm and was positioned in a room with prominent extra-maze cues. The platform was a clear Plexiglas stand (10 cm diameter, 26 cm high) that was positioned 26 cm from the maze wall in the southwest quadrant and held constant for each rat. Acquisition of spatial learning began on post-operative day 14 and consisted of providing a block of four daily trials for five consecutive days (14) (15) (16) (17) (18) to locate the escape platform when it was submerged 2 cm below the water surface. On day 19 the platform was raised 2 cm above the water surface to evaluate visible platform performance, which is incorporated as a control procedure to determine the contributions of non-spatial factors (e.g., sensory-motor function, motivation, and visual acuity) on cognitive performance. For each daily block of trials the rats were placed in the pool facing the wall at each of the four possible start locations (north, east, south, and west) in a quasi-randomized manner. Each trial lasted until the rat climbed onto the platform or until 120 s had elapsed, whichever occurred first. The rats that failed to locate the escape platform within the allotted time were manually guided to it. All rats remained on the platform for 30 s before being placed in a heated incubator between trials (4-min inter-trial interval). The times of the 4 daily trials for each rat were averaged and used in the statistical analyses.
Cognitive performance: memory retention
One day after the final acquisition training (day 19), all rats were given a single probe trial to measure memory retention. Briefly, the platform was removed from the pool and the rats were placed in the pool from the location point most distal to the quadrant where the platform was previously located (i.e., "target quadrant") and allowed to freely explore the pool for 30 s. The time spent searching in the target quadrant was recorded and used in the statistical analyses. The data were obtained using ANY-maze video tracking software.
Statistical analyses
All analyses were performed using Statview 5.0.1 software (Abacus Concepts, Inc., Berkeley, CA) on data collected by blinded experimenters. The motor and cognitive analyses were conducted using repeated-measures analysis of variance (ANOVA). The acute neurological data (i.e., hind limb withdrawal reflex and righting reflex) as well as the data for the visible platform, probe trial, and swim speed were analyzed using one-factor ANOVAs. When the overall ANOVA revealed significant effects, the Newman-Keuls post-hoc test, which controls for multiple comparisons and reduces the chance for a type 1 error, was used to determine specific group differences. The results are expressed as the mean ± standard error of the mean (S.E.M.) and were considered significant when p ≤ 0.05. 
Results
There were no exclusions and thus the statistical analyses were performed on the data from all 70 rats. No significant differences (p's > 0.05) were observed in any behavioral measure between the sham controls regardless of housing condition so their data were pooled into one group designated as SHAM.
Acute neurological function
No differences were observed among the TBI groups in hind limb withdrawal reflex after a brief paw pinch [left range = 158.1 ± 4.4 s to 164.4 ± 5.2 s, p > 0.05; right range = 153.2 ± 1.8 s to 160.1 ± 5.2 s, p > 0.05] or for righting reflex [range 346.2 ± 17.8 s to 380.1 ± 17.6 s, p > 0.05] following the termination of anesthesia. The lack of significant differences with these acute neurological indices suggests that all groups experienced equivalent levels of injury and anesthesia.
Motor function: beam-balance
Prior to surgery, each rat was able to balance on the beam for the allotted 60 s (Fig. 1) 
Motor function: beam-walk
Prior to surgery, each rat consistently traversed the 100 cm beam to the reward box in under 5 s (Fig. 2) quadrant, was observed only in the SHAM controls (36.8 ± 0.9%) relative to the TBI groups (Fig. 4) , which had a range of 24.6 ± 2.3% to 27.5 ± 2.7% and did not differ from one another [p > 0.05].
Discussion
Previous studies have shown that the typical APD HAL impairs motor and/or cognitive recovery after CCI [12, 13, 15, 19, 25] , fluid percussion [14] , and cortical ablation [27, 29] injury. HAL also attenuates the benefits of environmental enrichment, a preclinical model of neurorehabilitation that has been reported to confer significant motor, cognitive, and histological benefits after TBI [30, 31] . Moreover, the deleterious effects of HAL persist for up to 3 months after drug withdrawal [15] . In contrast, little is known about the prevalence or duration of any adverse effects of the atypical APD QUE treatment after TBI. However, the findings of several non-TBI studies suggest that it may preserve, and even improve, cognitive function. A prospective study of low-dose daily QUE for the treatment of aggressive symptoms three or more months after injury demonstrated that after six weeks of treatment, patients displayed improvement on measures of cognitive functioning [32] . Among a range of other APDs, QUE produced considerable improvement in global neurocognitive function in a clinical trial of patients with schizophrenia [33] . Rodent studies of both ketamine-induced and stress-induced cognitive impairments have also demonstrated that daily administration of QUE can mitigate performance deficits [34, 35] . Additionally, QUE has been shown to effectively reduce agitation and psychotic symptoms after TBI [36] . Taken together, these findings indicate that the mechanisms of QUE that attenuate agitation and aggression are independent of their effect on neurological functions. As such, QUE treatment may be a better alternative than HAL for managing agitated symptoms after TBI. Hence, the goal of this study was to describe the effects of daily and intermittent treatment with the APDs HAL and QUE on neurobehavioral and spatial learning after brain trauma produced by the well-established CCI injury paradigm.
Performance on the beam-balance and beam-walk motor tasks was relatively unaffected by the continuous or intermittent treatments when considering outcomes over the five days of testing. However, when performance was evaluated on the last day of testing, which is a critical endpoint measurement, there was a significant delay in traversing the beam for the TBI group receiving daily HAL, relative to the other TBI conditions. This finding suggests that daily HAL delays beam-walking performance and is in accord with previous CCI studies [12, 13, 15] . The acquisition of spatial learning was also substantially delayed in the HAL group treated once per day. No such delay was observed in the intermittent HAL group or the QUE-treated groups, regardless of administration paradigm (i.e., daily or intermittent).
These findings demonstrate that QUE, whether administered daily or intermittently after CCI, produces comparable behavioral and cognitive outcomes to those resulting from intermittent HAL treatment. Importantly, the behavioral results of these three treatment paradigms did not differ significantly from those observed in the VEH-treated TBI group. These data indicate that an intermittent treatment schedule with either QUE or HAL inhibits the deleterious cognitive and behavioral outcomes previously observed after daily administration with HAL or risperidone [12, 13, 15] . An intermittent administration schedule may present an alternative means of treatment with HAL to reduce agitation and aggression in TBI patients without compromising recovery. Additionally, these findings suggest that QUE may present a further treatment option, potentially with a more flexible variety of dosing schedules within a relative margin of safety for patient outcomes.
It is generally acknowledged that HAL exerts deleterious effects of functional outcome after experimental TBI by antagonizing D 2 receptors [6, 8, [12] [13] [14] [15] 18, 19, 25] . This theory is supported further by the plethora of data showing that D 2 receptor agonists, such as bromocriptine, methylphenidate, and amantadine enhance motor and cognitive performance after TBI [15, [37] [38] [39] [40] [41] . Moreover, the APD aripiprazole, which is a partial D 2 receptor agonist, does not impede recovery, but rather facilitates spatial learning after CCI injury [15] . QUE on the other hand exhibits moderate to high affinities for ␣1-adrenergic and 5-HT 2A receptors and lesser affinity for D 2 receptors [16, 17] . QUE also exhibits faster dissociation from the D 2 receptor versus HAL [42, 43] , which may be a mediating factor in its actions on behavioral outcomes after TBI and other disorders.
For example, it has been reported that QUE transiently disrupts avoidance behavior in a conditioned avoidance response task because it only transiently blocks D 2 receptors [44] . It has also been reported that QUE decreases object recognition deficits in a rat model of malformations of cortical development [26] , stressinduced spatial working memory impairment [45] , and reverses methamphetamine-induced cognitive deficits [46] . The benefits attributed to QUE could be due, in part to, to increased levels of DA in the frontal cortex. Specifically, Silverstone et al. reported that QUE and the 5-HT 1A receptor agonist buspirone significantly increased release of DA compared to controls [47] . However, there was no additive effect of the combined treatments, which lead the authors to suggest that the intrinsic partial 5-HT 1A agonist activity of QUE on its own may have led to a ceiling effect. Ichikawa et al. also reported an increase in DA release in the medial prefrontal cortex with QUE relative to saline controls [48] . These positive findings with QUE all have in common the same theme of increased DA neurotransmission that correlates with behavioral and cognitive improvement. It is possible that manipulating the dose of QUE may lead to behavioral improvement after TBI as was seen with the APD aripiprazole, which is also a partial 5-HT 1A receptor agonist. Indeed, 5-HT 1A receptor agonists have been reported numerous times to confer significant benefits after TBI [for comprehensive review,see 49] .
In conclusion, although, QUE did not increase cognitive performance after CCI, it also did not exacerbate TBI-induced cognitive and motor deficits as was seen with daily HAL in the current study and reported in others [12] [13] [14] [15] 18, 19, 25] . QUE may prove useful as an alternative APD treatment for management of agitation and aggression after clinical TBI. Furthermore, the data suggests that HAL may also be safe, but only if used sparingly.
